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Abstract
ATP and ADP are simultaneously released from activated platelets in equimolar concentrations. Micromolar concentra-
tions of ATP inhibit platelet aggregation by both competitive and non-competitive mechanisms. The current studies
addressed the question of how platelets respond to agonists in the presence of nanomolar and micromolar concentrations of
ATP and ADP alone or in combination. This is a significant issue since the concentration of ATP"ADP may vary widely
 .within a microenvironment depending upon the source and cause for the release of the nucleotides. ATP 1–10 nM was
found to significantly enhance the thromboxane A analog, U44619-, collagen- and thrombin-induced platelet aggregations.2
Conversely, ATP at 1–100 mM inhibited these same reactions. ADP, in general, behaved exactly opposite to ATP. When
equal amounts of ATP and ADP were added together the ADP response appeared to predominate. The observed
ATP-induced response was not due to a hydrolytic product as evidenced by an unaltered response to ATP in the presence of
 .adenosine deaminase or the ATP generating system, creatine phosphate plus creatine phosphokinase. Adenosine 1–10 nM ,
like ADP, inhibited agonist-induced platelet aggregation. The stimulation of agonist-induced platelet aggregation by 1–10
nM extracellular ATP appears to depend upon the phosphorylation of platelet membrane ecto proteins. The ATP analog,
bg-methylene ATP, that is incapable of serving as a phosphate donor for protein kinases, inhibited rather than stimulated
agonist-induced platelet aggregation. The dual response of platelets to low and high concentrations of extracellular
ATP"ADP may play a physiological role in hemostasis and thrombosis under normal and pathological conditions.
Keywords: Human platelet; Extracellular ATP; Aggregation
1. Introduction
An appreciation and understanding of the multi-
faceted roles of extracellular ATP within the cardio-
vascular system is slowly replacing the mistaken
dogma that ATP serves no physiological function
outside the cell. Since the early studies of Forrester,
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w xBurnstock and colleagues 1,2 described a physio-
logical role of extracellular ATP the number of re-
w xports in the literature dealing with the sources 3–9
 w x.and varied functions reviewed in 4,10,11 of this
nucleotide have greatly increased. The existence of
 .several different purinoceptors P was originally2
established based upon pharmacological analyses
w x2,3,10–12 and has subsequently been established by
w x w x w xcloning P 13,14 , P 15,16 and P 17,182x 2y 2u
purinoceptors from different species.
Platelets appear to possess a unique ADP receptor,
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w xP 4 , that when occupied by its ligand induces2T
w xplatelet aggregation 19 . Initially, it was presumed,
based upon studies with ADP, that extracellular ATP
antagonized various agonist-induced platelet re-
sponses solely by a competitive mechanism with
w xADP 20,21 . More recent evidence indicates that
while competition is the major mechanism of inhibi-
tion of ADP-induced platelet responses an additional
mechanism antagonizes other agonist responses via
w xATP binding to a second platelet P receptor 22–24 .2
This latter mechanism appears to involve the G pro-
w xtein coupled induction of cAMP 22,23 and inhibi-
w xtion of internal calcium mobilization 24 , inhibiting
 .collagen- thrombin- and U46619 TXA analog -in-2
duced platelet aggregations. The ATP response is
synergistic with a second potent physiological platelet
 . w xaggregation inhibitor, prostacyclin PGI 23 . The2
simultaneous presentation of PGI and ATP could2
play a significant role in limiting clot formation to
the site of vascular injury and excluding clot forma-
tion beyond the margin of disrupted endothelium.
At the site of a localized vascular injury the con-
centration of ATP would initially be very low, re-
leased from broken endothelial cells. This would be
followed by a steadily increasing concentration of
w xATP, potentially reaching levels of 20–50 mM 11 ,
released from activated platelets at the wound site.
Approximately equal molar concentrations of ADP
and ATP are stored in the dense granules and are
presumably released simultaneously from activated
w xplatelets 25 . This study addresses the potential ac-
 .  .tions of low 1–10 nM and high 1–100 mM
concentrations of extracellular ATP in the presence
and absence of ADP on platelet aggregation. It was
observed that high concentrations of ATP inhibited
platelet aggregation, as previously demonstrated
w x22,23 , however, low concentrations were stimula-
tory. The converse was true with ADP alone and
when ATP and ADP were present in equimolar con-
centrations the ADP effect predominated.
2. Methods
2.1. Sample preparation
 .Human blood 18–45 ml was collected by
venipuncture into plastic tubes containing 2–5 ml of
3.8% citrate yielding a 9:1 ratio of blood:citrate.
Blood was donated by normal adult volunteers all
signed consent forms in accordance with the Univer-
.sity Human Studies Committee , who had not taken
aspirin for at least 10 days. Platelet rich plasma
 . w xPRP was prepared as previously described 26 and
employed for aggregation studies with collagen or
U46619. Platelets were also washed as previously
w xdescribed 27 when aggregation studies were con-
ducted with thrombin. The washed platelet pellet was
re-suspended in Hepes Tyrode’s buffer 136 mM
NaCl, 2.7 mM KCl, 3.3 mM NaH PO , 1 mM2 4
.MgCl , 3.8 mM Hepes, pH 7.35 , containing 12
mgrml each of dextrose and BSA bovine serum
.albumin to yield a final concentration of 200–
300 000 plateletsrml.
2.2. Platelet aggregation
Platelet aggregation was measured on a Chronolog
 .Lumi aggregometer Chronolog, Haverford, PA at
378C as percent change in light transmission as previ-
w xously described 28 . Agonists employed in these
studies were collagen Sigma, bovine achilles tendon
.  . type I , a thromboxane A analogue U46619 Cay-2
. man Chem. Co. and thrombin Fibrindex, Ortho
.Diagnostic System . These agonists were added to
PRP or washed platelets in a final volume of 0.5 ml
to yield aggregations in the 40–50% range. Human
 .fibrinogen Sigma at a final concentration of 100
mgrml was added to the washed platelet prepara-
tions. The concentrations employed with collagen
ranged from 0.84 to 8.4 mgrml, for U46619 the
range was 0.5–1 mM and for thrombin the range was
0.05–0.1 Urml.
For experiments conducted in the presence of ade-
nine nucleotides, the tested reagents ATP, ADP, bg-
 .ATP bg-methylene ATP or a combination of an
 .equal amount of ATP and ADP AqA were added
1 min prior to the addition of agonists. Nucleotides
were serially diluted to yield final concentrations of
10y9–10y4 M for ATP or bg-ATP, 10y9–10y5 M
for ADP, and 5=10y9–5=10y5 M for AqA in
the reaction cuvette.
2.3. Data analysis
All the data were analyzed using an Excel statistic
program. Significance was determined by a one sided
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analysis of variance and a Bonferroni t-test. Signifi-
cance was taken as any value with P-0.05. All data
presented in the figures and the text are represented
as means"S.E.
3. Results
3.1. Effects of ATP, ADP, AqA on agonist-induced
platelet aggregation
Initially, we sought to determine if adenine nu-
cleotides in the range of 10y9–10y4 M modulated
agonist-induced platelet aggregations differentially at
 y9 y8 .  y6 y4 .low 10 –10 M vs. high 10 –10 M con-
centrations. ATP, ADP or AqA ATP plus ADP in
.a 1:1 ratio at different concentrations were added to
PRP 1 min prior to collagen. Fig. 1A illustrates that
collagen-induced platelet aggregation increased sig-
w  .xnificantly 12.06%"3.12 ns14 when ATP at
 y9 .low concentration 10 M was added. However,
increasing concentrations of ATP inhibited aggrega-
tion. At higher concentrations, ATP significantly in-
 .hibited the aggregation by 24.25%"7.34 ns9 at
y6  . y410 M to 86.94%"7.06 ns5 at 10 M. ADP,
on the other hand, significantly inhibited collagen-in-
 .duced platelet aggregation by 15.24%"13.22 ns7
 .to 31.09%"4.67 ns6 at low concentrations
 y9 y8 .10 –10 M but showed stimulation of 10.55%
 .  ."11.66 ns6 to 23.7% ns1 at higher concen-
 y6 y5 .trations 10 –10 M . The simultaneous addition
 .of equal amounts of ATP and ADP AqA , pre-
Fig. 1. The effect of ATP, ADP and AqA on agonist-induced
platelet aggregation. Varying concentrations of ATP, ADP or
AqA were added to platelet samples 1 min prior to the addition
of agonist. A. Collagen concentrations used with PRP were
varied between 0.84–8.4 mgrml to achieve 40–50% aggregation.
B. U46619 concentrations used with PRP were varied between
0.5 and 1 mM to achieve 40–50% aggregation. C. Thrombin
concentrations of 0.5–0.1 Urml were used with washed platelets
resuspended in Hepes Tyrode’s buffer to induce 40–50% aggre-
gation. The effects of the nucleotides were measured as % change
of platelet aggregation relative to control aggregations run in
parallel. All data are presented as means with error bars repre-
senting standard errors of the mean. The data points that are
 .significantly P -0.05 different than control are illustrated as
filled points. In general n varied between 4 and 10, however in a
few instances n was -4 or )10 the average sample size was
.approx. 6 .
sented the combined effect of both ATP and ADP.
However, the effect of ADP tended to dominate over
the ATP effect.
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Fig. 2. The effect of ATP on collagen- or U46619-induced
platelet aggregation in the presence and absence of adenosine
 .deaminase AD . ATP, adenosine and AD were added to PRP 1
 .  .min prior to A collagen or B U46619. The line through the
 .AD symbol I represents the fact that AD was added to the
control agonist-induced reaction and does not represent a point of
 .the graph relative to a concentration x-axis .
Fig. 3. The effect of ATP on collagen-induced platelet aggrega-
tion in the presence and absence of creatine phosphatercreatine
 .phosphokinase CPrCPK . ATP and CPrCPK were added 1 min
prior to collagen all with PRP.
The results of the effect of ATP, ADP, AqA on
U46619-induced platelet aggregation were similar to
those observed with collagen. As illustrated in Fig.
 y9 y8 .1B, ATP at low concentrations 10 –10 M sig-
nificantly stimulated the aggregation of platelets by
 .  .6.87%"2.44 ns10 and 14.44%"2.56 ns5 ,
 y6 y4respectively, while at high concentrations 10 –10
.M ATP significantly inhibited U46619-induced ag-
  . y5 .gregation 66.9%"16.01 ns4 at 10 M . ADP,
in contrast to ATP, again inhibited the aggregation at
 y9 y8 .low concentrations 10 –10 M by 12.96%"
 .  .6.29 ns8 and 33.7%"10.9 ns9 , respectively,
and stimulated the aggregation at high concentrations
 y6 y5 .10 –10 M . When equal concentrations of ATP
 .and ADP AqA were added 1 min prior to U46619,
the effect of ADP was again dominant over the effect
of ATP, as shown in Fig. 1B.
The third agonist used in this study was thrombin.
Platelets had to be washed to remove interfering
coagulation proteins for these studies. As for the
above aggregation studies, ATP, ADP or AqA at
different concentrations were added 1 min prior to
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the addition of thrombin. The stimulation of throm-
 .bin-induced platelet aggregation Fig. 1C at low
concentrations of ATP was less than that observed
with PRP aggregations induced by either collagen or
U46619. The stimulation by ATP at 10y9 M was
 . only 5.16%"2.37 ns9 and 6.42%"2.83 ns
. y8  .12 at 10 M P value 0.03 and 0.01, respectively .
High concentrations of ATP again showed significant
inhibition of thrombin-induced aggregations with a
 . y5level of 44%"13.3 ns7 at 10 M ATP. Inhibi-
tion was not due to ATP inhibition of thrombin
amidolytic activity as assayed with the chromogenic
thrombin substrate, CBS 34.47 H-D-cyclohexylgly-
cyl-L-a-aminobutyryl-L-arginine-paranitroanilide, Di-
. w xagnostica Stago, Asnieres, France 27 .`
The effect of ADP on thrombin-induced aggrega-
tions with washed platelets was different than with
collagen or U46619 with PRP. At low concentrations
ADP had no significant effect on the aggregation
induced by thrombin while at high concentrations a
greater stimulation was observed. AqA, at low con-
centrations, was found to stimulate thrombin-induced
aggregations of washed platelets slightly as opposed
to the inhibition observed with collagen and U46619.
Therefore, the ATP effect predominated in the mix-
ture with thrombin as the agonist as opposed to ADP
predominating with the other two agonists. AqA at
 y6 y5 .high concentrations 5=10 –5=10 M showed
stimulation of 17–29.6% as compared to control in a
fashion similar to that observed with collagen and
U46619.
3.2. Effect of adenosine deaminase
Since ATP, ADP and AMP in peripheral tissues
may be subjected to extracellular breakdown by ec-
w xtonucleotidases to adenosine 29,30 , it was important
to determine whether the effects produced by the
adenine nucleotides were caused by the individual
nucleotides or were produced by their hydrolysis to
adenosine. Initially, adenosine at various concentra-
 y9 y5 .tions 10 –10 M was added to PRP 1 min prior
to the addition of collagen. The results showed that
adenosine, unlike ATP or ADP, inhibited the aggre-
gation induced by collagen or U46619 at both low
 .and high concentrations Fig. 2 . The inhibitory effect
of adenosine was completely blocked by the addition
 .of 4.8 Urml of adenosine deaminase AD . Adeno-
sine deaminase alone at this concentration had no
effect on aggregation.
ATP at different concentrations, together with 4.8
Urml of AD was added to PRP 1 min prior to the
 .addition of collagen or U46619. Fig. 2 A, B illus-
trates the results of the effect of ATP in the presence
and absence of adenosine deaminase. In both experi-
ments, the addition of adenosine deaminase plus ATP
to PRP did not change the effect of ATP, at the low
concentration, to stimulate nor, at the high concentra-
tion to inhibit the aggregation induced by collagen or
U46619. The results of a representative experiment
done twice are presented.
3.3. Effect of creatine phosphatercreatine phospho-
( )kinase CPrCPK
To further confirm that the stimulation and inhibi-
tion observed with ATP at low and high concentra-
Fig. 4. The comparison of the effect of bg-ATP vs. the effect of
 .ATP on collagen-induced platelet aggregation. ATP others is
data from Fig. 1 compiled from other aggregation measurements
induced by collagen and included for comparative purposes. ATP
 .same is obtained from the same PRP preparation used to study
bg-ATP. All data are presented as in Fig. 1.
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 .  .Fig. 5. HPLC analysis of extracellular ATP and ADP added to washed platelets and platelet poor plasma PPP . 1 mM ATP A or 1 mM
 .  .ADP B were incubated in: buffer control ; with washed platelets that had been preincubated for 30’ with 10 mM dipyridamole, or; with
 .PPP for 5 min at 378C. Sample preparation is described in text. Samples were separated on a C18 column 25 cm=4.6 mm with Buffer
 .1: 60 mM ammonium dihydrogen phosphate, 1 mM tetrabutylammonium dihydrogen phosphate TBAP , pH 5.0. Buffer 2: methanol, 1
 .  .mM TBAP, gradient 95% Buffer 1: 5% Buffer 2“80% Buffer 1: 20% Buffer 2 and a flow rate of 2 mlrmin. Sample C was PPP,
without added nucleotide, that contained 254 nm absorbing bands of unknown identity. ATP eluted at 22 min and ADP at 16 min.
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tions were the direct effect of ATP itself and not a
hydrolytic product, a single additional experiment
was conducted. A combination of CPrCPK was used
to continuously convert the first possible ATP hydro-
lytic product, ADP back to ATP. CPrCPK 3.1 mM
.of CP and 2 Urml of CPK was added to PRP 1 min
prior to the addition of collagen and used as the
control. As shown in Fig. 3, this amount of CPrCPK
did not effect the aggregation. Then ATP, at low or
high concentrations, together with CPrCPK was
added to PRP 1 min prior to the addition of collagen.
As illustrated in Fig. 3, addition of CPrCPK did not
change the stimulation by ATP at the low concentra-
 y9 .tion 10 M nor the inhibition by high concentra-
 y5 .tion 10 M of collagen-induced platelet aggrega-
tions.
3.4. Effect of bg-ATP on collagen-induced platelet
aggregation
ATP modulates many cellular processes via pro-
tein phosphorylation. This study was conducted to
determine if protein phosphorylation by ATP might
also modulate platelet aggregation. bg-ATP contains
a methylene group instead of oxygen between the b
and g phosphate positions and, therefore, cannot
serve as a phosphate donor. bg-ATP at low concen-
 y9 y8 .trations 10 –10 M was added to PRP 1 min
prior to the addition of collagen. The results were
compared with the effect of ATP at the same concen-
tration and illustrated in Fig. 4. As observed above,
ATP at low concentrations stimulated the aggregation
 . y9by 6.39%"2.33 ns12 at 10 M and 9.18%"
 . y81.76 ns6 at 10 M. The ATP data obtained in
this experiment was compared to the composite ATP
data depicted in Fig. 1 which was presented as ATP
 .others . In contrast, addition of bg-ATP at the same
 y9 y8 .concentrations 10 –10 M showed no stimula-
tion of collagen-induced aggregations but rather inhi-
 . bition 4.08%"2.76 ns7 and 11.20%"3.99 n
.s6 , respectively.
3.5. HPLC analysis of ATP and ADP
A final set of experiments were conducted to
ascertain if added extracellular ATP andror ADP
were hydrolyzed during the 4 min incubation of
platelets with added agonists. Washed platelets
 .  .300 000rml and platelet poor plasma PPP were
incubated with 1 mM ATP or ADP for 5 min at 378C.
The platelets were pelleted at 16 000=g for 2 min.
The platelet supernatants and the PPP samples were
then centrifuged through Amicon 3 K spin filters
 .concentrators at 16 000=g for 20 min to exclude
molecules greater than 3000 mol wt. from the fil-
trates. The ATP and ADP content in the filtrates were
 .analyzed by HPLC Waters and detected at 254 nm.
Results depicted in Fig. 5 demonstrated that neither
nucleotide, under the experimental conditions em-
ployed in these studies, were appreciably hydrolyzed
by potential ecto-nucleotidase activity.
4. Discussion
The results of this study demonstrated that extra-
cellular ATP at low and high concentrations differen-
tially modulates platelet aggregation induced by sev-
eral physiological agonists. Extracellular ATP has
been widely accepted as a competitive antagonist of
ADP-induced platelet aggregations due to competi-
tion with ADP for P receptors on the surface of2 T
w xplatelets 31 . However, a non-competitive mecha-
nism for the inhibitory effect of ATP has also been
w xdemonstrated with agonists other than ADP 22–24 .
The current study demonstrated that extracellular
 .ATP, at high concentrations 1–100 mM , signifi-
cantly inhibited platelet aggregation, as previously
w xshown 22,23 with a nearly linear dose response
curve between 1 and 100 mM ATP with collagen and
U46619. The inhibitory response to ATP was dis-
placed one log step higher when thrombin was the
agonist. In all cases low concentrations of ATP 1–10
.nM significantly stimulated agonist-induced platelet
aggregations. These differential responses to extracel-
lular ATP may play a significant physiological role in
platelet activation associated with hemostasis and
thrombosis under normal and pathological conditions.
This is the first report of a stimulatory effect of
extracellular ATP on agonist-induced platelet aggre-
gation. Lower levels of stimulation by ATP were
observed with washed platelets induced to aggregate
by thrombin than by collagen or U46619 with PRP
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samples. The reduced stimulation may be due to the
washing procedure in which contributory plasma fac-
 .tor s were removed. It is also possible that the
different mechanisms of aggregation induced by
thrombin, collagen or U46619 responded differen-
tially to extracellular ATP or the washing procedures
reduced platelet responsiveness. At 100 nM concen-
tration the ATP did not significantly alter platelet
aggregation induced by the three agonists. This prob-
ably resulted from an increased variation of data at
this pivotal region where transition of the dual effects
of ATP occurred. The dual effects of ATP are likely
to be independent of released granule ATP, ADP.
Extracellular ATP was added prior to the agonist,
therefore, the ATP-induced modification of the
platelet preceded agonist-induced aggregation. Any
subsequent influence of released components on
platelet aggregation would occur equally in the con-
trol sample as well as the adenine nucleotide treated
sample.
In general, ADP effects were the opposite of ATP.
ADP significantly inhibited agonist-induced platelet
 .aggregation at low concentrations 1–10 nM and
stimulated the aggregation at high concentrations 1–
.10 mM . However, ADP stimulated thrombin-in-
 .duced platelet aggregations with washed platelets
throughout the concentration range employed. This
difference in response to ADP may arise from the use
of different agonists andror the washing protocol.
 .The effect at high concentrations 1–10 mM of ADP
to further stimulate platelet aggregation induced by
collagen, U46619 and thrombin were significant.
However, this is to be expected since we employed
suboptimal concentrations of agonists and ADP nor-
mally induces platelet aggregation in this micromolar
range. Therefore, the final level of platelet aggrega-
tion with these samples was merely due to the com-
bined activity of the two agonists. However, the
 .effect of ADP at low concentrations 1–10 nM to
inhibit platelet aggregation induced by collagen and
U46619 was unexpected. Inhibition may have re-
sulted from desensitization of platelets with subopti-
mal exposure to the agonist, ADP. In any case, the
response to ATP versus ADP was clearly distinct and
argues against the hydrolysis of ATP to ADP under
our experimental conditions. The data for the addition
 .of equal amounts of ADP and ATP AqA sug-
gested that the effect of AqA tended to follow that
of ADP. This indicated that the inhibitory effect of
ADP could negate the ATP-induced stimulation of
platelet aggregation when present simultaneously.
As in various types of tissues, the study of effects
induced by ATP or other nucleotides are complicated
because many purinoceptors are able to bind ATP,
ADP, AMP and their analogs with varying potencies.
Furthermore, ATP, ADP and AMP in peripheral tis-
sues may be hydrolyzed to adenosine by ectonu-
w xcleotidases 29,30 . Therefore, it was important to
verify that the effects of ATP observed in this study
were caused solely by ATP and not by ADP nor
adenosine. Unlike the dual effects of ATP or ADP
observed in these studies, adenosine at both low
 .  .1–10 nM and high concentrations 1–100 mM
inhibited agonist-induced platelet aggregation in a
dose response fashion. This was consistent with pre-
vious studies that demonstrated an A -receptor-medi-2
w xated response to adenosine 10 . The inhibition of
agonist-induced platelet aggregation observed with
both 1 mM and 10 mM adenosine were completely
reversed by the addition of adenosine deaminase. In
contrast, the effects of ATP at both low and high
concentrations were unaltered by the addition of
adenosine deaminase indicating that the dual effects
of ATP were directly due to extracellular ATP and
not due to hydrolysis to adenosine. The results at
high concentrations of ATP, in the presence and
absence of adenosine deaminase corresponded to pre-
w xvious findings by Soslau et al. 23 . Furthermore, the
effect of ATP was unlikely to be complicated by the
formation of ADP as indicated by studies with
CPrCPK. Finally, HPLC studies demonstrated for
the first time, that ATP or ADP were not appreciably
hydrolyzed by washed platelets or plasma during the
4 min incubation period employed in our studies.
We previously demonstrated that surface platelet
proteins could be phosphorylated by extracellular
w xATP 22 . The results from studies using bg-ATP
implied that protein phosphorylation was associated
with the ATP regulation of agonist-induced platelet
aggregation. bg-ATP at low concentrations 1–10
.nM inhibited collagen-induced platelet aggregation
rather than stimulate. Since the g-phosphate of bg-
ATP cannot be enzymatically transferred to phospho-
rylate proteins, these results implied that phosphory-
lation was important for the stimulation of platelet
aggregation by low concentrations of ATP. A grow-
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ing number of reports indicate that the phosphoryla-
tion state of ecto cell surface proteins modulates
w xplatelet functions 32,33 as well as a variety of cell
w xfunctions 34 .
It must be emphasized, at this time, that phospho-
rylation of surface platelet proteins appears to be
involved in the stimulatory effect of ATP on agonist-
induced aggregations, however, the results do not
unequivocally prove it. The protein kinase C in-
 .hibitor, H7 at 50–100 mM , completely inhibited the
phosphorylation of three surface proteins 53, 75 and
. 85 kDa in a 10 min labeling experiment procedure
w x.as previously described 22 with extracellular g-
32P-ATP while )200 mM HA1004 was required to
 .effect similar inhibitions data not shown . The ki-
nase inhibitor studies indicate that a protein kinase
with a kinase C-like activity may be associated with
the extracellular protein phosphorylation process,
however, much work remains to prove this point. It is
interesting to note that phosphorylation of intra-
cellular platelet proteins are similarly inhibited by H7
w xbut not by HA1004 35 .
The dual effects of ATP and ADP on platelet
function may indicate that low concentrations of ex-
tracellular ATP initially available at the site of vessel
injury could help promote platelet aggregation via
phosphorylation of selected surface proteins. As
platelets continue to aggregate, the ATP concentra-
w xtion could reach 20–50 mM at the site of injury 11 .
This ATP would then bind to P receptors stimulating2
w xcAMP 22,23 and inhibiting calcium mobilization
w x24 thereby limiting further recruitment of platelets.
The metabolite of ATP, adenosine, is also a potent
aggregation inhibitor and could, if formed, further
reinforce the inhibitor actions of ATP. The opposing
effects of ADP and ATP in the same concentration
range indicate that the two nucleotides might play a
key role in the fine tuning control of hemostasis and
thrombosis. It should be noted that while these stud-
ies demonstrated that platelets and plasma have little
or no ecto nucleotidase activity, other cells within the
w xcardiovascular system may have high activities 10 .
These active ecto nucleotidases may rapidly effect
the ATPrADP ratio at sites of blood vessel injury.
Any imbalance of the ATPrADP ratio could shift the
level of platelet aggregation. However, this specula-
tion needs more information to determine how much,
from what source and at what stage ATP and ADP
may impact on hemostasis and thrombosis.
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